Xencor (XNCR)
(Real Time Quote from BATS)
$7.46 USD
-0.49 (-6.16%)
Updated Aug 6, 2025 03:55 PM ET
After-Market: $7.50 +0.04 (0.54%) 4:14 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XNCR 7.46 -0.49(-6.16%)
Will XNCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XNCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XNCR
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
XNCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
Xencor (XNCR) Upgraded to Buy: Here's Why
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
Other News for XNCR
Xencor reports Q2 EPS (41c) , consensus (71c)
Bank of America Securities Sticks to Their Buy Rating for Xencor (XNCR)
Xencor’s Promising Developments in Autoimmune and Oncology Drive Buy Rating
Incyte granted FDA label expansion for lymphoma therapy Monjuvi
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward